Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation
Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 15 Sept 2026, 11:44 pm
Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation The US FDA concluded an inspection of Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited鈥攁 wholly owned subsidiary of Aurobindo Pharma鈥攍ocated at Kazipally Industrial Area, Telangana, conducted between 7th Sep'26 and 15th Sep'26. The inspection closed with one procedural observation. The company stated it will submit a response to the US FDA within the stipulated timeline while maintaining robust quality and compliance standards across its manufacturing operations.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
